EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Antibody‐Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds

Aniruddha Adhikari iD, Irene A Chen iD

Small · 2025-04 · 21 (15)

DOI: 10.1002/smll.202409635 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Small, online erschienen am 06.03.2025. Verfasst von Aniruddha Adhikari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, Department of Chemistry and Biochemistry, University of California, Los Angeles, CA, 90049, USA. Hauptthemen laut MEDLINE: Nanoparticles, Antibodies, Monoclonal. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 321 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies (mAbs) and antibody fragments have revolutionized medicine as highly specific binding agents and inhibitors. At the same time, several types of nanomaterials, including liposomes, lipid nanoparticles (NPs), polymersomes, metal and metal oxide NPs, and protein nanostructures, are increasingly utilized and explored for therapeutic potential due to their versatility, chemical and physical properties, and tunability. However, nanomaterials alone often lack specificity, leading to relatively low efficacy and/or high toxicity. To address this problem, a rapidly emerging area is antibody‐nanomaterial conjugates (ANCs), which combine the precise targeting specificity of antibodies with the effector functionality of the nanomaterial. In this review, we give a brief introduction to mAbs and major conjugation techniques, describe major classes of nanomaterials being studied for therapeutic potential, and review the literature on ANCs of each class. Special focus is given to emerging applications including ANCs addressing the blood‐brain barrier, ANCs delivering nucleic acids, and light‐activated ANCs. While many disease targets are related to cancer, ANCs are also under development to address autoimmune, neurological, and infectious diseases. While important challenges remain, ANCs are poised to become a next‐generation therapeutic technology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesAntibodies, MonoclonalHumansAnimals

Stichwörter der Autor:innen

antibodybioconjugationliposomemAbnanoparticle

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, Department of Chemistry and Biochemistry, University of California, Los Angeles, CA, 90049, USA.

ORCID-Profile: Aniruddha Adhikari, Irene A Chen

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Adhikari, A., & Chen, I. A. (2025). Antibody‐Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds. Small, 21(15). https://doi.org/10.1002/smll.202409635

Vancouver

Adhikari A, Chen IA. Antibody‐Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds. Small. 2025;21(15). doi:10.1002/smll.202409635

BibTeX
@article{Adhikari2025,
  author = {Adhikari, Aniruddha and Chen, Irene A},
  title = {Antibody‐Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds},
  journal = {Small},
  year = {2025},
  volume = {21},
  number = {15},
  doi = {10.1002/smll.202409635}
}
Kostenlos starten →